• 
• Case-Based Modules
• Initial Evaluation
• Dermatologic Manifestations
• Oral Manifestations
• OIs: Prophylaxis
• OIs: Treatment
• Antiretroviral Rx
• Antiretroviral Rx: Resistance
• Antiretroviral Rx: Adverse Effects
• Drug-Drug Interactions
• Postexposure Prophylaxis
• Perinatal Transmission
• Special Populations
• Prevention for Positives
• Challenging Unknowns
• Resource-Limited Settings
• Interactive Tutorials
• Routine HIV Screening
• Oraquick Advance Rapid HIV Test
• HIV Integration
• This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.

• Home
• About This Site
• Free CE
• AETC NRC
• Resources
• Feedback
• Site Map
• Authors

Perinatal Transmission

Question | Discussion | References | CME Credit

Case 1: Antiretroviral Therapy During Pregnancy to Prevent Perinatal HIV Transmission

You answered:

	Start zidovudine (Retrovir) monotherapy. Consider adding lamivudine (Epivir) in the third trimester.

This answer is incorrect. Combination antiretroviral therapy is indicated in pregnancy in women who meet criteria for their own treatment or when they have a HIV-RNA greater than 1000 copies/ml.

	No antiretroviral therapy is indicated at this stage of the pregnancy. Consider starting antiretroviral therapy if the mother’s HIV RNA increases to greater than 50,000 copies/ml.
	Start zidovudine plus lamivudine (Combivir) plus nevirapine (Viramune). Consider switching nevirapine to efavirenz (Sustiva) if she does not tolerate nevirapine.
	Start stavudine (Zerit) plus lamivudine (Epivir) plus nelfinavir (Viracept). Consider switching stavudine to zidovudine (Retrovir) if the anemia improves significantly.
	Start stavudine (Zerit) plus didanosine (Videx EC) plus nelfinavir (Viracept).

[Back to Case 1 Question | Go to Correct Answer]

Disclaimer | Privacy Policy Copyright © 2004-2013 University of Washington